BioSpace News Archive

Agreement with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited, a subsidiary of Lee’s Pharmaceutical Holdings Limited, provides license to IC 265 and IC 270, novel first-in-class therapies being developed for dry eye and allergic conjunctivitis, respectively, in China, a major growth market, and Southeast Asia [28-July-2020] IRVINE, Calif. and HONG KONG , July

- Positive top-line results show upadacitinib (15 mg and 30 mg) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in adult and adolescent patients with moderate to severe atopic dermatitis versus placebo plus TCS[1] - Safety results were consistent with the other two studies in the Phase 3 program for atopic dermatitis[1-3] - RINVOQ, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is currently approved for

- TrialSpark’s integrated tech platform and trial model will enable resTORbio to accelerate their clinical trials of RTB-101 for COVID-19 in community/outpatient settings. [28-July-2020] NEW YORK , July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announ

Devonian Health Group Inc. announces the issuance of the following units in settlement of interests owed to a holder of debentures issued in the private placement, as announced by press releases dated July 19, 2018

Phase 1 Trial for the Treatment of Patients with Acute Lung Injury Due to COVID 19 Anticipated to Begin in Third Quarter of 2020

American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company focused on supporting novel therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that on July 15, 2020, the last patient last visit (LPLV) marked the final step toward the completion of the ABV-1505 Phase II Part I clinical trial for the treatment of adult ADHD.

Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately. “We welcome Tony to the board as a new independent director and look forward to the leadership he will bring,” said David Phillips, Chairman of Meridian Bioscience. “We were looking to add diagnostics expertise to the board and Tony additionally brings the breadth of leading both large and small public organiza

Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2020. The call can be accessed by dialing 1-877-451-6152 (U.S. and Canada) or 1-201-389-0879 (international). The passcode for the conference call is 13706729. To access the live webcast or the subsequent arch

Paper supports use of nVNS as a front-line therapy for acute and preventative treatment of cluster headache and as an effective option for the treatment of migraine headache

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its prophylactic breast cancer vaccine is making progress towards clinical trials.